Attached files
file | filename |
---|---|
EX-31.2 - EXHIBIT 31.2 - ACURA PHARMACEUTICALS, INC | tv490022_ex31-2.htm |
EX-31.1 - EXHIBIT 31.1 - ACURA PHARMACEUTICALS, INC | tv490022_ex31-1.htm |
EX-23.1 - EXHIBIT 23.1 - ACURA PHARMACEUTICALS, INC | tv490022_ex23-1.htm |
EX-10.34 - EXHIBIT 10.34 - ACURA PHARMACEUTICALS, INC | tv490022_ex10-34.htm |
10-K - FORM 10-K - ACURA PHARMACEUTICALS, INC | tv490022_10k.htm |
EXHIBIT 32
CERTIFICATION OF
CHIEF EXECUTIVE OFFICER
AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert B. Jones, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Acura Pharmaceuticals, Inc. for the fiscal year ended December 31, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Form 10-K fairly presents, in all material respects, the financial condition Acura Pharmaceuticals, Inc. as of the dates presented and results of operations of Acura Pharmaceuticals, Inc. for the periods presented.
June 7, 2018 | By: | /s/ Robert B. Jones |
Robert B. Jones | ||
President and Chief Executive Officer |
I, Peter A. Clemens, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Acura Pharmaceuticals, Inc. for the fiscal year ended December 31, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Form 10-K fairly presents, in all material respects, the financial condition Acura Pharmaceuticals, Inc. as of the dates presented and results of operations of Acura Pharmaceuticals, Inc. for the periods presented.
June 7, 2018 | By: | /s/ Peter A. Clemens |
Peter A. Clemens | ||
Senior Vice President and Chief Financial Officer |